首页> 美国卫生研究院文献>Springer Open Choice >Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment
【2h】

Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment

机译:弥漫性神经胶质瘤患者的肿瘤相关神经认知功能障碍:抗肿瘤治疗之前神经认知功能的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Deficits in neurocognitive functioning (NCF) frequently occur in glioma patients. Both treatment and the tumor itself contribute to these deficits. Data about the role of the tumor are scarce, because NCF has mostly been studied postoperatively. We aimed to summarize data on pre-treatment NCF in glioma patients and to determine the overall and domain-specific prevalence of neurocognitive dysfunction. We searched PubMed and Embase according to PRISMA-P protocol for studies that evaluated pre-treatment NCF in glioma patients (1995-November 2016) and extracted information about NCF. We performed analysis of data for two main outcome measures; mean cognitive functioning of the study sample (at group level) and the percentage of impaired patients (at individual level). We included 23 studies. Most studies were small observational prospective cohort studies. In 11 (47.5%) studies, patient selection was based on tumor location. NCF was analyzed at the group level in 14 studies, of which 13 (92.9%) found decreased NCF at group level, compared to normative data or matched controls. The proportion of individuals with decreased NCF was reported in 15 studies. NCF was impaired (in any domain) in 62.6% of the individuals (median; interquartile range 31.0–79.0). Cognitive impairments were more common in patients with high-grade glioma than with low-grade glioma (OR 2.50; 95% CI 1.71–3.66). Cognitive impairment occurs in the majority of treatment-naive glioma patients, suggesting that neurocognitive dysfunction is related to the tumor. However, the literature about pre-treatment NCF in glioma patients is characterized by small-scale studies and strong heterogeneity in patient selection, resulting in high risk of bias.Electronic supplementary materialThe online version of this article (doi:10.1007/s11060-017-2503-z) contains supplementary material, which is available to authorized users.
机译:神经胶质瘤患者经常发生神经认知功能障碍。治疗和肿瘤本身都是造成这些缺陷的原因。关于NCF的作用的数据很少,因为NCF已经在术后进行了研究。我们旨在总结神经胶质瘤患者治疗前NCF的数据,并确定神经认知功能障碍的总体和特定领域患病率。我们根据PRISMA-P协议搜索PubMed和Embase进行了研究,以评估神经胶质瘤患者的治疗前NCF(1995年11月2016年11月),并提取有关NCF的信息。我们对两个主要结果指标进行了数据分析。研究样本的平均认知功能(在小组水平)和受损患者的百分比(在个体水平)。我们纳入了23项研究。大多数研究是小型观察性前瞻性队列研究。在11(47.5%)个研究中,患者的选择基于肿瘤的位置。在14项研究中对NCF进行了分组分析,其中13份(92.9%)与标准数据或相匹配的对照组相比,发现NCF降低了。 15项研究报告了NCF降低的个体比例。 NCF受损(在任何领域)的个体为62.6%(中位数;四分位间距为31.0-79.0)。高级别神经胶质瘤患者的认知障碍较低级别神经胶质瘤患者更为常见(OR 2.50; 95%CI 1.71–3.66)。大多数未接受过治疗的神经胶质瘤患者都发生认知障碍,这表明神经认知功能障碍与肿瘤有关。然而,有关神经胶质瘤患者治疗前NCF的文献的特点是研究规模小且患者选择上的异质性强,导致偏倚风险高。电子补充材料本文的在线版本(doi:10.1007 / s11060-017- 2503-z)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号